DexCom (DXCM) said late Friday it was notified earlier this week by the US Food and Drug Administration that its facilities in Mesa, Arizona, and San Diego were found to have non-conformities in manufacturing processes and quality management system during inspections last year.
The warning letter will not restrict its ability to produce, market, manufacture or distribute products nor will it require DexCom to recall any products, the company said in a filing with the US Securities and Exchange Commission.
DexCom also said it does not expect the regulatory notice to have a material impact on its operations or financial guidance for fiscal 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。